πŸ”‘ Key Learning

  • Chronic autoimmune symmetrical polyarthritis, classically affecting small joints (MCPs, PIPs, wrists) but sparing the DIPJs
  • Presents with morning stiffness > 1 hour, joint swelling and pain
  • Antibodies: RhF, anti-CCP
  • Managed with DMARDs and bridging steroids; biologics in refractory cases

🧬 Pathophysiology

  • Autoimmune synovial inflammation β†’ joint destruction
  • Progressive cartilage and bone erosion if untreated

πŸ‘€ Clinical Features

  • Peak onset: 30–50 years, Female > Male (3:1)
    • HLA-DR4 association
  • Symmetrical small joint pain/swelling: MCP, PIP, wrists, MTPs
    • Spares DIPJs
  • Morning stiffness > 1 hour
  • Joint deformities in advanced disease:
    • BoutonniΓ¨re deformity
    • Swan-neck deformity
  • Rheumatoid nodules (extensor surfaces)
  • Positive squeeze test
  • Warm, boggy joints
Swan neck deformity in a 65 year old Rheumatoid Arthritis patient. User:Phoenix119, CC BY-SA 3.0, via Wikimedia Commons

   

πŸ§ͺ Investigations

  • Bloods:
    • 1st line: Rheumatoid factor - positive in 7/10 people with RA
      • An IgM antibody which reacts with IgG
      • Prognostic marker - high RhF levels associated with progressive disease
    • 2nd line: If RhF negative, measure anti-cyclic citrullinated peptide antibodies (anti-CCP)
    • CRP/ESR are commonly elevated
  • XR: Juxtaarticular osteoporosis

πŸ’₯ Management of Flares

  • 1st Line: Short-term treatment with steroids
    • Intra-articular glucocorticoid if localised flare
    • IM glucocorticoid if IA is not possible - methylprednisolone, triamcinolone 
    • PO glucocorticoid if not practical to give IM
  • Consider offering an NSAID for short term symptomatic relief with PPI

πŸ’Š Long-term Management

  • 1st Line: DMARD monotherapy (methotrexate, sulfasalazine, leflunomide) at diagnosis
    • Methotrexate is commonly given 1st line for RA
    • Consider hydroxychloroquine for palindromic rheumatism
    • Consider bridging steroid when commencing DMARD
  • 2nd Line: Combination of 2 DMARDs
  • 3rd Line: Add biological DMARDs:
    • TNF inhibitors: etanercept, infliximab, adalimumab
    • Other biologics: rituximab, abatacept

πŸ§ͺ DMARD Side Effects

DMARDSide Effects
MethotrexateMyelosuppression, liver cirrhosis, pneumonitis/fibrosis
  - Monitor FBC, LFTs
SulfasalazineOligospermia, Heinz body anaemia, ILD
LeflunomideHTN, hepatotoxicity, ILD
HydroxychloroquineRetinopathy, corneal deposits

   

🀰 RA in Pregnancy

  • Safe DMARDs: Sulfasalazine, Hydroxychloroquine (SHafe in pregnancy))
  • Avoid: Methotrexate, Leflunomide

🫁 Extra-Articular Features

🫁 Respiratory

  • Pulmonary fibrosis
  • Pleural effusions (exudative)
  • Caplan syndrome (RA + coal dust exposure)
  • Pulmonary nodules
  • Bronchiolitis obliterans

πŸ‘ Ocular

  • Keratoconjunctivitis sicca (most common)
  • Scleritis / episcleritis
  • Corneal ulcers

❀️ Other

  • Accelerated CV disease
  • Osteoporosis
  • Depression
  • Felty's syndrome (RA + splenomegaly + neutropenia)
  • AA amyloidosis

πŸ”„ Palindromic Rheumatism

  • Relapsing/remitting monoarthritis (large joints)
  • Tx: Hydroxychloroquine, other DMARDs if required

πŸ“ Exam Clues & Clinchers

  • Symmetrical small joint pain, sparing DIPJs, with stiffness > 1 hour in morning
  • Antibodies: RhF +ve  - if negative check anti-CCP = highly specific
  • Treatment: Methotrexate is 1st line; avoid in pregnancy